EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Risk factors of short-term colectomy following Janus kinase inhibitor therapy in acute severe ulcerative colitis: a systematic review and meta-analysis of individual-level data from real-world studies

Yuntao Zou, David I Fudman iD, Shrinivas Bishu iD, Jeffrey A Berinstein iD, Ezra Burstein iD, Moheb Boktor iD, Jianyi Yin iD

Crohn’s & Colitis 360 · 05.10.2026 · 8 (4)

DOI: 10.1093/crocol/otag120 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Crohn’s & Colitis 360, online erschienen am 23.10.2026. Verfasst von Yuntao Zou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hospital Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, United States. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Emerging evidence supports the use of Janus kinase inhibitors (JAKi) in acute severe ulcerative colitis (ASUC). However, risk factors associated with non-response and the need for short-term colectomy in ASUC patients treated with JAKi remain poorly understood.

Methods

We conducted a systematic review and individual-level data meta-analysis of real-world studies evaluating tofacitinib or upadacitinib for the treatment of ASUC. The primary and secondary outcomes were colectomy within 30 days and 12 weeks, respectively. Generalized linear mixed-effects models were used for univariable and multivariable analyses to estimate odds ratios (ORs). A stratified Cox proportional hazards model was used to assess colectomy-free survival.

Results

Twenty-three studies with 145 patients were included (69.0% treated with tofacitinib, 31.0% with upadacitinib). The overall colectomy rate was 13.1% within 30 days and 20.5% within 12 weeks. In univariable analyses, prior exposure to anti-tumor necrosis factor (TNF) therapy before ASUC hospitalization was statistically significantly associated with lower odds of colectomy within 30 days (OR 0.44, P = .006) and 12 weeks (OR 0.51, P = .008). Prior anti-TNF exposure remained significantly associated with lower odds of colectomy in multiple multivariable analyses. No other clinical or laboratory variables were significantly associated with primary/secondary outcomes.

Conclusions

Prior anti-TNF exposure before hospitalization is associated with lower short-term colectomy rates in ASUC patients treated with JAKi. Our findings highlight the need for future studies to optimize the position of JAKi in the ASUC management algorithm and to identify novel predictive biomarkers to advance precision medicine strategies.

Schlagwörter

Stichwörter der Autor:innen

JAK inhibitoracute severe ulcerative colitismeta-analysistofacitinibupadacitinib

Autor:innen und Institutionen

  • Division of Hospital Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, United States.
  • Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.
  • Divison of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.

ORCID-Profile: David I Fudman, Shrinivas Bishu, Jeffrey A Berinstein, Ezra Burstein, Moheb Boktor, Jianyi Yin

Förderung

  • NIDDK NIH HHS
  • National Institutes of Health

Zitieren

APA

Zou, Y., Fudman, D. I., Bishu, S., Berinstein, J. A., Burstein, E., Boktor, M., & Yin, J. (2026). Risk factors of short-term colectomy following Janus kinase inhibitor therapy in acute severe ulcerative colitis: a systematic review and meta-analysis of individual-level data from real-world studies. Crohn’s & Colitis 360, 8(4). https://doi.org/10.1093/crocol/otag120

Vancouver

Zou Y, Fudman DI, Bishu S, Berinstein JA, Burstein E, Boktor M, et al. Risk factors of short-term colectomy following Janus kinase inhibitor therapy in acute severe ulcerative colitis: a systematic review and meta-analysis of individual-level data from real-world studies. Crohn’s & Colitis 360. 2026;8(4). doi:10.1093/crocol/otag120

BibTeX
@article{Zou2026,
  author = {Zou, Yuntao and Fudman, David I and Bishu, Shrinivas and Berinstein, Jeffrey A and Burstein, Ezra and Boktor, Moheb and Yin, Jianyi},
  title = {Risk factors of short-term colectomy following Janus kinase inhibitor therapy in acute severe ulcerative colitis: a systematic review and meta-analysis of individual-level data from real-world studies},
  journal = {Crohn’s & Colitis 360},
  year = {2026},
  volume = {8},
  number = {4},
  doi = {10.1093/crocol/otag120}
}
Kostenlos starten →